{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:02:36Z","timestamp":1793962956993,"version":"4.8.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cytogfr.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:19:21Z","timestamp":1622164761000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-1395","authenticated-orcid":false,"given":"Rossella","family":"Talotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erle S.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2021.05.001_bib0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00108-020-00834-9","article-title":"Epidemiologie von SARS-CoV-2-Infektion und COVID-19","volume":"61","author":"Salzberger","year":"2020","journal-title":"Internist (Berl)."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25813","article-title":"Epidemiological analysis of COVID\u201019 and practical experience from China","volume":"92","author":"Ye","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620943293","article-title":"COVID-19-Associated coagulopathy: an exacerbated immunothrombosis response","volume":"26","author":"Jayarangaiah","year":"2020","journal-title":"Clin. Appl. Thromb."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0025","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0030","article-title":"Lupus anticoagulant is frequent in patients with Covid\u201019","author":"Harzallah","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0035","article-title":"Thromboembolism, hypercoagulopathy, and antiphospholipid antibodies in critically Ill coronavirus disease 2019 Patients: a before and after study of enhanced anticoagulation","volume":"2","author":"van der Linden","year":"2020","journal-title":"Crit. Care Explor."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1097\/MBC.0000000000000963","article-title":"Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit","volume":"32","author":"Hamad\u00e9","year":"2021","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1744666X.2019.1546578","article-title":"Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts","volume":"15","author":"Lackner","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2005.10.004","article-title":"The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity","volume":"210","author":"Harel","year":"2005","journal-title":"Immunobiology"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0055","series-title":"EMA\/PRAC\/157045\/2021 Pharmacovigilance Risk Assessment Committee (PRAC). Signal Assessment Report on Embolic and Thrombotic Events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) \u2013 COVID-19 Vaccine AstraZeneca (Other Viral Vaccines)","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0060","series-title":"COVID-19 Vaccine (Ad26.COV2-S [recombinant]) RISK MANAGEMENT PLAN (RMP)","year":"2021"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0065","series-title":"Janssen COVID-19 Vaccine Frequently Asked Questions","author":"FDA","year":"2021"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0070","series-title":"COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare Blood Clots With Low Blood Platelets","author":"European Medicines Agency","year":"2021"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0075","first-page":"524","article-title":"Women\u2019s issues in antiphospholipid syndrome","volume":"18","author":"Papadakis","year":"2016","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.trsl.2020.04.006","article-title":"Antiphospholipid syndrome","volume":"225","author":"Petri","year":"2020","journal-title":"Transl. Res."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0090","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-018-0773-x","article-title":"Role of infectious diseases in the antiphospholipid syndrome (Including its catastrophic variant)","volume":"20","author":"Mendoza-Pinto","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0100","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.disamonth.2003.10.001","article-title":"Antiphospholipid syndrome","volume":"49","author":"Gezer","year":"2003","journal-title":"Dis. Mon."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ddmec.2004.11.006","article-title":"Pathogenic mechanisms of antiphospholipid syndrome: a new autoimmune disease","volume":"1","author":"Meroni","year":"2004","journal-title":"Drug Discov. Today Dis. Mech."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/jth.13320","article-title":"Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma","volume":"14","author":"Lackner","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1160\/TH-16-11-0858","article-title":"Extracellular nucleic acids in immunity and cardiovascular responses: between alert and disease","volume":"117","author":"Preissner","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0125","first-page":"3527","article-title":"Endothelial cells in physiology and in the pathophysiology of vascular disorders","volume":"91","author":"Cines","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0167-4838(99)00266-6","article-title":"Regulation of blood coagulation","volume":"1477","author":"Esmon","year":"2000","journal-title":"Biochim. Biophys. Acta - Protein Struct. Mol. Enzymol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev.med.47.1.315","article-title":"Role of endothelium in thrombosis and hemostasis","volume":"47","author":"Wu","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0145","first-page":"157","article-title":"Expression of endothelial cell IgG Fc receptors and markers on various cultures","volume":"112","author":"Pan","year":"1999","journal-title":"Chin. Med. J. (Engl)."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0150","series-title":"Rheumatology","author":"Hochberg","year":"2019"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0155","doi-asserted-by":"crossref","first-page":"31113","DOI":"10.1074\/jbc.272.49.31113","article-title":"Immune clearance of phosphatidylserine-expressing cells by phagocytes: the role of \u03b22-glycoprotein I in macrophage recognition","volume":"272","author":"Balasubramanian","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/antib6010004","article-title":"Neutrophil extracellular traps, antiphospholipid antibodies and treatment","volume":"6","author":"Bravo-Barrera","year":"2017","journal-title":"Antibodies"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09801-x","article-title":"Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome","volume":"10","author":"Ali","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.3363","article-title":"Anti\u2010\u03b22GPI\/\u03b22GPI induces human neutrophils to generate NETs by relying on ROS","volume":"37","author":"You","year":"2019","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0175","doi-asserted-by":"crossref","DOI":"10.1002\/art.41057","article-title":"Increased adhesive potential of antiphospholipid syndrome neutrophils mediated by \u03b22 integrin Mac\u20101","volume":"72","author":"Sule","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1097\/MOH.0b013e3282ab9904","article-title":"Secondary immune thrombocytopenic purpura","volume":"14","author":"Liebman","year":"2007","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0185","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2017.1280150","article-title":"The role of platelets in antiphospholipid syndrome","volume":"28","author":"Baroni","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-017-0678-0","article-title":"New insights on platelets and platelet-derived microparticles in systemic lupus erythematosus","volume":"19","author":"Scherlinger","year":"2017","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0195","doi-asserted-by":"crossref","DOI":"10.1111\/joim.13228","article-title":"The pathogenesis of microthrombi in COVID\u201019 cannot be controlled by DOAC: NETosis should be the target","volume":"289","author":"Gremese","year":"2021","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0200","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.632677","article-title":"An update on antiviral therapy against SARS-CoV-2: how far have we come?","volume":"12","author":"Indari","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0205","doi-asserted-by":"crossref","DOI":"10.1136\/jim-2020-001628","article-title":"Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia","author":"Carallo","year":"2021","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0210","article-title":"Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study","author":"Shao","year":"2020","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-020-02228-y","article-title":"COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature","volume":"50","author":"Tan","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584241","article-title":"Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome","volume":"11","author":"Borghi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0225","article-title":"Original article: murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with \u03b22-Glycoprotein I: its characteristics and role in molecular mimicry","volume":"61","author":"Inic-Kanada","year":"2008","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0897.2010.00922.x","article-title":"Induction of APS after TTd hyper-immunization has a different outcome in BALB\/c and C57BL\/6 mice","volume":"65","author":"Zivkovic","year":"2011","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0235","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2016.04.014","article-title":"Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine","volume":"53","author":"Bizjak","year":"2016","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0240","doi-asserted-by":"crossref","DOI":"10.1177\/0961203311429554","article-title":"Influenza vaccination can induce new-onset anticardiolipins but not \u03b22-glycoprotein-I antibodies among patients with systemic lupus erythematosus","volume":"21","author":"Vista","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0245","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0b013e32835448b8","article-title":"Infections and vaccines in the etiology of antiphospholipid syndrome","volume":"24","author":"Cruz-Tapias","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0250","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0260","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1128\/JVI.02819-06","article-title":"Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver","volume":"81","author":"Stone","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166393","article-title":"Safety and immunogenicity of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC 012)","volume":"11","author":"Crank","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0270","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.urology.2005.04.041","article-title":"Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants","volume":"66","author":"Malaeb","year":"2005","journal-title":"Urology."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0275","first-page":"1","article-title":"A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination","author":"Greinacher","year":"2021","journal-title":"Res. Sq."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0280","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","article-title":"\u03b22 glycoprotein I (\u03b22GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0285","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0290","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0295","first-page":"1","article-title":"Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine","author":"Carli","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0300","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.bbadis.2014.07.021","article-title":"Role of extracellular and intracellular microRNAs in sepsis","volume":"1842","author":"Essandoh","year":"2014","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0305","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/clinchem\/48.8.1212","article-title":"Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals","volume":"48","author":"Ng","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0310","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1042\/BJ20041021","article-title":"Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP)","volume":"385","author":"Nakazawa","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0315","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0320","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1160\/TH10-06-0345","article-title":"Expression and localisation of vascular ribonucleases in endothelial cells","volume":"105","author":"Fischer","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0325","series-title":"Current Topics in Microbiology and Immunology","doi-asserted-by":"crossref","DOI":"10.1007\/82_2020_217","article-title":"Formulation and delivery technologies for mRNA vaccines","author":"Zeng","year":"2020"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases,\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102311","article-title":"Type I interferon gene expression in antiphospholipid syndrome: pathogenetic, clinical and therapeutic implications","volume":"104","author":"Xourgia","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00464-5","article-title":"18F-fluorodeoxyglucose PET\/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine","volume":"397","author":"Steinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0345","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.121.262108","article-title":"FDG avid axillary lymph nodes after COVID-19 vaccination","author":"Johnson","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0350","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-021-05278-3","article-title":"COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET\/CT in a patient affected by melanoma","author":"Avner","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0355","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003635","article-title":"COVID-19 vaccination manifesting as incidental lymph nodal uptake on 18F-FDG PET\/CT","author":"Ahmed","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0360","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1111\/jth.13072","article-title":"A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles","volume":"13","author":"Wu","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0365","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0370","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.thromres.2014.11.027","article-title":"Endothelial and platelet microparticles in patients with antiphospholipid antibodies","volume":"135","author":"Breen","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.01.057","article-title":"General determination of causation between Covid-19 vaccines and possible adverse events","volume":"39","author":"Hampton","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0385","series-title":"Vaccines and Related Biological Products Advisory Committee Meeting February 26","author":"FDA","year":"2021"},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0390","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0395","first-page":"97","article-title":"Anti-idiotype antibodies and circulating immune complexes after immunisation with tetanus-toxoid","volume":"39","author":"Kamath","year":"1994","journal-title":"Ceylon Med. J."},{"key":"10.1016\/j.cytogfr.2021.05.001_bib0400","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood.2019001133","article-title":"FcRn augments induction of tissue factor activity by IgG-containing immune complexes","volume":"135","author":"Cines","year":"2020","journal-title":"Blood."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610121000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:58:17Z","timestamp":1761217097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610121000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":80,"alternative-id":["S1359610121000423"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.05.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}